Literature DB >> 24682845

Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection.

S Rantala1.   

Abstract

The importance of group C and G Streptococcus dysgalactiae subspecies equisimilis (S. dysgalactiae subsp. equisimilis) as a significant pathogen has recently been better recognized. S. dysgalactiae subsp. equisimilis disease can range in severity from milder skin and soft-tissue conditions such as wound infection, erysipelas, and cellulitis, to life-threatening necrotizing fasciitis and streptococcal toxic shock syndrome, thus sharing the clinical picture with S. pyogenes. The most common clinical manifestation of bacteremia is cellulitis. An increase in the incidence of S. dysgalactiae subsp. equisimilis bacteremia has been recognized. Invasive forms of this infection are most commonly found in elderly patients with underlying comorbidities and skin breakdown. The case fatality in bacteremia has been reported to be 15-18%. In this review, the epidemiology, clinical characteristics, and emm types of S. dysgalactiae subsp. equisimilis bacteremia are summarized.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682845     DOI: 10.1007/s10096-014-2092-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  50 in total

1.  Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes.

Authors:  Anders Jensen; Mogens Kilian
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

3.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  In vitro bactericidal synergy of gentamicin combined with penicillin G, vancomycin, or cefotaxime against group G streptococci.

Authors:  K Lam; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

Review 5.  Invasive infection caused by Streptococcus dysgalactiae subsp. equisimilis: characteristics of strains and clinical features.

Authors:  Takashi Takahashi; Kimiko Ubukata; Haruo Watanabe
Journal:  J Infect Chemother       Date:  2010-07-06       Impact factor: 2.211

6.  Virulence profiling of Streptococcus dysgalactiae subspecies equisimilis isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases.

Authors:  Mark R Davies; David J McMillan; Robert G Beiko; Vanessa Barroso; Robert Geffers; Kadaba S Sriprakash; Gursharan S Chhatwal
Journal:  Clin Infect Dis       Date:  2007-04-19       Impact factor: 9.079

7.  Population genetics of Streptococcus dysgalactiae subspecies equisimilis reveals widely dispersed clones and extensive recombination.

Authors:  David J McMillan; Debra E Bessen; Marcos Pinho; Candace Ford; Gerod S Hall; José Melo-Cristino; Mário Ramirez
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

Review 8.  What happened to the streptococci: overview of taxonomic and nomenclature changes.

Authors:  Richard Facklam
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  emm gene diversity, superantigen gene profiles and presence of SlaA among clinical isolates of group A, C and G streptococci from western Norway.

Authors:  B R Kittang; S Skrede; N Langeland; C G Haanshuus; H Mylvaganam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-20       Impact factor: 3.267

10.  Complete genome sequence of Streptococcus dysgalactiae subsp. equisimilis 167 carrying Lancefield group C antigen and comparative genomics of S. dysgalactiae subsp. equisimilis strains.

Authors:  Shinya Watanabe; Teruo Kirikae; Tohru Miyoshi-Akiyama
Journal:  Genome Biol Evol       Date:  2013       Impact factor: 3.416

View more
  29 in total

1.  Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features.

Authors:  Anna Bläckberg; Bo Nilson; Volkan Özenci; Lars Olaison; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-08       Impact factor: 3.267

2.  Recurrent SDSE bacteraemia resulting in streptococcal toxic shock syndrome in a patient with Noonan syndrome.

Authors:  Kei Suzuki; Akiko Nakamura; Ken Ishikura; Hiroshi Imai
Journal:  BMJ Case Rep       Date:  2016-08-02

3.  Incidence, clinical characteristics, and outcomes of Streptococcus dysgalactiae subspecies equisimilis bacteremia in a tertiary hospital: comparison with S. agalactiae bacteremia.

Authors:  Joung Ha Park; Jiwon Jung; Min Jae Kim; Heungsup Sung; Mi-Na Kim; Yong Pil Chong; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-07       Impact factor: 3.267

4.  Streptococcus dysgalactiae subsp. equisimilis from invasive and non-invasive infections in Spain: combining epidemiology, molecular characterization, and genetic diversity.

Authors:  Beatriz Rojo-Bezares; Laura Toca; José Manuel Azcona-Gutiérrez; Nerea Ortega-Unanue; Paula Toledano; Yolanda Sáenz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-03       Impact factor: 3.267

5.  Prevalence and molecular diversity of invasive Streptococcus dysgalactiae and Streptococcus pyogenes in a German tertiary care medical centre.

Authors:  S Rößler; R Berner; E Jacobs; N Toepfner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-03       Impact factor: 3.267

6.  Lack of Opsonic Antibody Responses to Invasive Infections With Streptococcus dysgalactiae.

Authors:  Anna Bläckberg; Therese de Neergaard; Inga-Maria Frick; Pontus Nordenfelt; Rolf Lood; Magnus Rasmussen
Journal:  Front Microbiol       Date:  2021-04-27       Impact factor: 5.640

7.  Erysipelas, a large retrospective study of aetiology and clinical presentation.

Authors:  Anna Bläckberg; Kristina Trell; Magnus Rasmussen
Journal:  BMC Infect Dis       Date:  2015-09-30       Impact factor: 3.090

8.  Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.

Authors:  Trond Bruun; Oddvar Oppegaard; Bård R Kittang; Haima Mylvaganam; Nina Langeland; Steinar Skrede
Journal:  Open Forum Infect Dis       Date:  2015-11-25       Impact factor: 3.835

9.  Molecular Characterization of Invasive Streptococcus dysgalactiae subsp. equisimilis, Japan.

Authors:  Takeaki Wajima; Miyuki Morozumi; Shigeo Hanada; Katsuhiko Sunaoshi; Naoko Chiba; Satoshi Iwata; Kimiko Ubukata
Journal:  Emerg Infect Dis       Date:  2016-02       Impact factor: 6.883

10.  Increased cytotoxicity and streptolysin O activity in group G streptococcal strains causing invasive tissue infections.

Authors:  Nikolai Siemens; Bård R Kittang; Bhavya Chakrakodi; Oddvar Oppegaard; Linda Johansson; Trond Bruun; Haima Mylvaganam; Mattias Svensson; Steiner Skrede; Anna Norrby-Teglund
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.